Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 1Other hematologic neoplasm 1Other 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Pathologic Complete Response 1Neoplasms 1Carcinoma in Situ 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Diphenhydramine × Genitourinary × Clear all
NCT00887640 2014-02-26

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Duke University

Phase 2 Terminated
11 enrolled 9 charts
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡